Asamura H, Okada M, Saji H, et al. Randomized trial of segmentectomy compared to lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Presented at: 101st Annual Meeting of the American Association of Thoracic Surgery. April 30-May 2, 2021.
Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (Impower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy: the phase32 PORT-C randomized clinical trial. JAMA Oncol. 2021;7:1178.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
Rosell R, Gómez-Codina J, Camps, C, et al. A randomized trial comparing perioperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-158.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976.
Huynh C, Walsh LA, Spicer JD. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:563-580.
Hellmann MD, Chaft JE, William WB Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-50.
Ferreira V, Minnella EM, Awasthi R, et al. Multimodal prehabilitation for lung cancer surgery: a randomized controlled trial. Ann Thorac Surg. 2021;112:1600-1608.
Schmid S, Minnella EM, Najmeh S, et al. Neoadjuvant prehabilitation therapy for locally advanced non-small-cell lung cancer: optimizing outcomes through the trajectory of care. Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract e20545.
Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2019;157:743-753.
ClinicalTrials.gov. A study of atezolizumab as neoadjuvant and adjuvant therapy in resectable non-small cell lung cancer (NSCLC) – Lung cancer mutation consortium (LCMC3). clinicaltrials.gov/ct2/show/NCT02927301. Accessed November 16, 2021.
Lee JM, Chaft J, Nicholas A, et al: Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. Presented at: 22nd World Conference On Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS02.05.
Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786-795.
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413-1422.
Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 checkmate 816 trial. Presented at: American Association for Cancer Research Annual Meeting 2021; April 10-15, 2021. Abstract CT003.
Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 checkMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract 8503.
ClinicalTrials.gov. A neoadjuvant study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in early stage non-small cell lung cancer (NSCLC) (checkmate 816). clinicaltrials.gov/ct2/show/NCT02998528. Accessed November 16, 2021.
Lim EK, Batchelor TJ, Dunning J, et al. Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: one-year results from a randomized controlled trial (VIOLET). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting. June 4-8, 2021. Abstract 8504.
Yoshino I, Yokoyama H, Yano T. Comparison of surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol. 1997;64:32-35.
Frick AE, Lüders H, Leschber G. Thirty and 90-day mortality after lung cancer resection in 2242 patients. Presented at: 2015 European Lung Cancer Conference. April 15-18, 2015. Abstract 620.
Blumenthal GM, Bunn PA Jr, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13:1818-1831.